Skip to main content

$0.024 (0%)

High

$0.03

Low

$0.02

Trades

24

Turnover

$54,432

Volume

2,170,184
30 June 2023 at 3:59pm
Register to track 1AD and receive email alerts.

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. AdAlta Limited has collaborative partnerships with GE Healthcare Technologies Inc to develop i-body enabled PET imaging agents for use in immuno-oncology; and Carina Biotech Pty Ltd to develop CAR-T cell therapies for solid tumor. The company was incorporated in 2006 and is based in Bundoora, Australia.

Expand Company Description

Market Cap (10-Oct)

$12,124,120 (1,598th)

Close (30-Jun)

$0.024

Volume (30-Jun)

2,170,184

Shortsold (2-Feb)

3,141 (0.00%) (662nd)

52w High

$0.041

52w Low

$0.016

P/E

-

EPS

-0.01
Subject
1AD Ann: AD-214 clinical trial approval

1AD Ann: Change in substantial holding

1AD Ann: Change in substantial holding

1AD Ann: Change of Director's Interest Notice x 2 (TO & DF)

1AD Ann: Top 20 Option Holders & Distribution Schedule

1AD Ann: Application for quotation of securities - 1AD

1AD Ann: Investor Summit live and recorded presentation

1AD Ann: Investor presentation

1AD Ann: Rights Offer results

1AD Ann: Notice of change of exercise price of options

1AD Ann: Despatch of Rights Offer documentation

1AD Ann: Investor Presentation - Rights Offer Webinar

1AD Ann: Letter to Ineligible Foreign Shareholders

1AD Ann: Application for quotation of securities - 1AD

1AD Ann: Letter to Eligible Shareholders

1AD Ann: Letter to Optionholders

1AD Ann: Target Market Determination

1AD Ann: Prospectus

1AD Ann: Proposed issue of securities - 1AD

1AD Ann: Rights Offer to fund early return to clinic and growth

1AD Ann: Quarterly Appendix 4C and Activities Report

1AD Ann: Notification of cessation of securities - 1AD

1AD Ann: Notification regarding unquoted securities - 1AD

1AD Ann: Final Director's Interest Notice

1AD Ann: Retirement of Non-Executive Director

1AD Ann: ShareCafe webinar presentation 3 Mar 2023

1AD Ann: Half Yearly Report and Accounts

1AD Ann: Spark Plus Singapore Investor Presentation

1AD Ann: Becoming a substantial holder

1AD Ann: Cleansing Notice under Section 708A

1AD Ann: Application for quotation of securities - 1AD

1AD Ann: Application for quotation of securities - 1AD

1AD Ann: Proposed issue of securities - 1AD

1AD Ann: Proposed issue of securities - 1AD

1AD Ann: Quarterly Appendix 4C and Activities Report

1AD Ann: Change in substantial holding

1AD Ann: Publication highlights I-body potential in osteoporosis

1AD Ann: Change of Director's Interest Notice x 2

1AD Ann: AdAlta welcomes new substantial shareholders

1AD Ann: Ceasing to be a substantial holder

1AD Ann: Second Japan patent for AD-214

1AD Ann: Results of Meeting

1AD Ann: Chair address and CEO presentation to AGM

1AD Ann: AD-214 progress and priorities webinar presentation

1AD Ann: AD-214 progress and priorities

1AD Ann: Balance of R&D Tax Incentive Refund received

1AD Ann: Quarterly Appendix 4C and Activities Report

1AD Ann: Letter to Shareholders, Notice of AGM & Proxy Form

1AD Ann: 1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer

1AD Ann: Notification of cessation of securities - 1AD

Register to track 1AD and receive email alerts.

Similar Companies

CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX